ArticleMolecular biology reports2025
Characterization of two glycosyltransferases that modulate withanolide biosynthesis and defense in Withania somnifera.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Phylogenomics and metabolic engineering reveal a conserved gene cluster in Solanaceae plants for withanolide biosynthesis.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe medicinal properties of Ashwagandha (Withania somnifera) are attributed to the presence of triterpenoid withanolides and their glycosylated forms, withanosides. Withanosides are proposed to be formed from withanolides by the action of glycosyltransferases (GTs). METHODS AND
resultsTwo genes encoding GTs (WsGT4 and WsGT6) from W. somnifera were identified and characterized using Escherichia coli expressed recombinant proteins and in-planta studies. Biochemical assays with recombinant proteins showed that WsGT4 catalyzed product formation using withanolide A, withanolide B, withanone, and 12-deoxywithastramonolide as substrates and UDP-glucose serving as the glucose donor. While, WsGT6 catalyzed the product formation only with withaferin A as a substrate employing either UDP-glucose or UDP-galactose as sugar donors. Quantitative real-time analysis showed that transcripts of WsGT4 and WsGT6 were induced in response to methyl jasmonate treatment and prominent in leaves as compared to other tissues. Modulating the expression of WsGT4 and WsGT6 by virus-induced gene silencing (VIGS) and transient overexpression significantly affected the levels of withanolides and withanosides in the leaves. Furthermore, silencing either WsGT4 or WsGT6 in W. somnifera reduced the tolerance to Pseudomonas syringae DC3000 growth, while their overexpression enhanced the tolerance to the bacterium.
conclusionsOur results indicate the role of WsGT4 and WsGT6 in withanoside biosynthesis and in defense against a bacterial pathogen in W. somnifera. These GTs could be utilized for targeted modulation of withanolides in cell cultures or at the whole-plant level and for enhancing tolerance against bacterial pathogens and improving the yield of withanosides.
Indexed as
Identifiers
40616712What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.